You are here

  • Home
  • Archive
  • Volume 8, Issue Suppl 3
  • 790 A phase II study (TACTI-002) of eftilagimod alpha (a soluble LAG-3 protein) with pembrolizumab in PD-L1 unselected patients with metastatic non-small cell lung(NSCLC) or head and neck carcinoma(HNSCC)

Article Text

Article menu

Download PDFPDF

Late-breaking abstracts
Clinical trials completed
790 A phase II study (TACTI-002) of eftilagimod alpha (a soluble LAG-3 protein) with pembrolizumab in PD-L1 unselected patients with metastatic non-small cell lung(NSCLC) or head and neck carcinoma(HNSCC)
  1. Matthew Krebs1,
  2. Margarita Majem2,
  3. Enriqueta Felip3,
  4. Martin Forster4,
  5. Bernard Doger5,
  6. Tim Clay6,
  7. Enric Carcereny7,
  8. Julio Peguero8,
  9. Leora Horn9,
  10. Pawan Bajaj10,
  11. Patricia Roxburgh11,
  12. Chrystelle Brignone12,
  13. Christian Mueller13 and
  14. Frederic Triebel13
  1. 1The Christie NHS Foundation Trust, Manchester, Manchester, UK
  2. 2Hospital de la Santa Creu i Sant Pau, Barcelona, Spain
  3. 3Vall d’ Hebron Institute of Oncology, Barcelona, Spain
  4. 4University College London Hospitals NHS, London, UK
  5. 5Fundacion Jimenez Díaz, Madrid, Spain
  6. 6St John of God Subiaco Hospital, Perth, Australia
  7. 7Institut Català d’Oncologia Badalona, Badalona, Spain
  8. 8Oncology Consultants, P.A., Houston, Texas, USA
  9. 9Vanderbilt University Medical Center (VU, Nashville, TN, USA
  10. 10Tasman Oncology, Queensland, Australia
  11. 11Beatson West of Scotland Cancer Center, Glasgow, UK
  12. 12Immutep S.A.S, Paris, France
  13. 13Immutep, Berlin, Germany

Abstract

Background Eftilagimod alpha (efti) is a soluble LAG-3 protein that binds to a subset of MHC class II molecules to mediate antigen presenting cell (APC) and CD8 T-cell activation. The stimulation of the dendritic cell network and subsequent T cell recruitment may lead to stronger anti-tumor responses in combination with pembrolizumab than observed with pembrolizumab alone. We report results from stage 1 of all parts of the study (NCT03625323).

Methods Patients (pts) with unselected PD-L1 expression were recruited into 3 cohorts: part A; 1st line, immunotherapy naïve NSCLC; part B; 2nd line, immunotherapy refractory NSCLC and part C; 2nd line immunotherapy naive HNSCC. The study uses a Simon’s 2-stage design, with objective response rate (ORR) by iRECIST as the primary endpoint (EP). Secondary EPs include tolerability, disease control rate (DCR), progression free survival (PFS), overall survival (OS), PK, PD and immunogenicity. Fifty-eight (58) pts were recruited into stage 1. Up to additional 51 pts will be recruited if a pre-specified ORR threshold is met for the respective part. Efti is administered as 30 mg subcutaneous injection every 2 wks for 8 cycles and then every 3 wks for 9 cycles; pembrolizumab is administered at 200 mg intravenous infusion every 3 wks for up to 2 yrs. The study was approved by ethic committees and institutional review boards.

Results Between Mar 2019 and Jul 2020 88 pts were enrolled. The median age was 67 yrs (range 53-84) and 70% were male. ECOG PS 0:1 was 42% and 58% respectively. Pts from all PD-L1 tumor expression subgroups were recruited. Pts received a median of 4 (1-25) pembrolizumab and 5.5 (1-22) efti administrations. The most common (≥ 15%) treatment emergent adverse events (TEAEs) were asthenia (28%), cough (27%), decreased appetite (22%), dyspnea (21%), fatigue (18%) and diarrhea (15%). Three (3) pts discontinued due to treatment related AEs. The ORR (acc. to iRECIST) of the 58 patients enrolled into stage 1 is shown in (table1). PK profiles after the first or repeated efti dosing were in line with previous studies, with a mean Cmax at7 ng/ml reached ≤ 24h. Circulating TH1 biomarkers 2 weeks after the last efti administration were increased (3 months vs. baseline) by a mean 61% and 209% for CXCL10 (Student paired t-test, p=0.02, n=31) and IFN-γ(p= 0.02, n=19), respectively.

View this table:
Abstract 790 Table 1

ORR (acc. to iRECIST) of the 58 patients enrolled into stage 1

Conclusions Efti plus pembrolizumab is safe and shows encouraging antitumor responses in NSCLC and HNSCC patients

Trial Registration NCT03625323

Ethics Approval The study was approved by relevant ethic committees and institutional review boards.

http://creativecommons.org/licenses/by-nc/4.0/

This is an open access article distributed in accordance with the Creative Commons Attribution 4.0 Unported (CC BY 4.0) license, which permits others to copy, redistribute, remix, transform and build upon this work for any purpose, provided the original work is properly cited, a link to the licence is given, and indication of whether changes were made. See: https://creativecommons.org/licenses/by/4.0/.

https://doi.org/10.1136/jitc-2020-SITC2020.0790

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.